Clinical trial
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With…
NCT00045201 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00045201 |
|---|---|
| Title | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Solid Neoplasm |
| Intervention type | Drug |
| Interventions | Erlotinib Hydrochloride, Irinotecan Hydrochloride |
| Enrollment | 60 |
| Start date | Jun 13, 2002 |
| Primary completion | Sep 13, 2013 |
| Completion | Aug 22, 2026 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 4, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: